Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment. (October 2016)

• Record Type: Journal Article
• Authors: Smit, Roelof AJ; Postmus, Iris; Trompet, Stella; Barnes, Michael R; Warren, Helen; Arsenault, Benoit J; Chasman, Daniel I; Cupples, L Adrienne; Hitman, Graham A; Krauss, Ronald M; Li, Xiaohui; Psaty, Bruce M; Stein, Charles M; Rotter, Jerome I; Jukema, J Wouter
• Is Part Of: Pharmacogenomics. Volume 17:Number 15(2016)
• Page Start: 1621
• Page End: 1628
• Publication Date: 2016-10
• Subjects: MR–Egger -- pharmacogenetics -- statin therapy; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2016-0091
• Languages: English
• ISSNs: 1462-2416

Abstract

Aims: To utilize previously reported lead SNPs for low-density lipoprotein cholesterol (LDL-c) levels to find additional loci of importance to statin response, and examine whether genetic predisposition to LDL-c levels associates with differential statin response.Methods: We investigated effects on statin response of 59 LDL-c SNPs, by combining summary level statistics from the Global Lipids Genetics and Genomic Investigation of Statin Therapy consortia.Results: Lead SNPs for APOE, SORT1 and NPC1L1 were associated with a decreased LDL-c response to statin treatment, as was overall genetic predisposition for increased LDL-c levels as quantified with 59 SNPs, with a 5.4% smaller statin response per standard deviation increase in genetically raised LDL-c levels.Conclusion: Genetic predisposition for increased LDL-c level may decrease efficacy of statin therapy.